SCHEMBL3636581

SCHEMBL3636581

O=C(CNc1c(Cl)cccc1Cl)Oc1ccccc1.[NaH]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 1/20 0.41
PTK2B Q14289 1/20 0.41
LMNA P02545 3/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
TTR P02766 2/20 0.40
AKR1B10 O60218 1/20 0.40
UGT1A9 O60656 1/20 0.40
TRPA1 O75762 1/20 0.40
ABCB11 O95342 1/20 0.40
MT-CO2 P00403 1/20 0.40
ALB P02768 1/20 0.40
CXCL8 P10145 1/20 0.40
UGT1A6 P19224 1/20 0.40
UGT1A1 P22309 1/20 0.40
PTGS1 P23219 1/20 0.40
CXCR1 P25024 1/20 0.40
ADRA1A P35348 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3396111 0.98 KMT2A (0.43) KMT2AMEN1MAPTPTK2BLMNA
SCHEMBL28535131 0.97 KMT2A (0.42) KMT2AMEN1MAPTPTK2BLMNA
SCHEMBL7164936 0.83 MEN1 (0.54) KMT2AMEN1MAPTLMNANPC1
SCHEMBL6243396 0.76 CYP19A1 (0.46) KMT2AMEN1MAPTLMNANPC1
SCHEMBL8370090 0.76 KMT2A (0.57) KMT2AMAPTLMNATTRAKR1B10
SCHEMBL7759545 0.76 HTT (0.45) KMT2ALMNARAB9ATTRAKR1B10
SCHEMBL6243149 0.76 MEN1 (0.51) KMT2AMEN1MAPTLMNANPC1
SCHEMBL8365425 0.76 KMT2A (0.50) KMT2AMEN1LMNATTRAKR1B10
SCHEMBL27926510 0.74 CYP19A1 (0.47) KMT2AMEN1MAPTLMNARAB9A
SCHEMBL16672098 0.73 KMT2A (0.58) KMT2AMEN1MAPTLMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4245752-A2 PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES Techfields Inc (US) 2023-09-20 EP disclosed
CN-116350597-A Preparation method of diclofenac sodium sustained-release preparation 珠海润都制药股份有限公司 2023-06-30 CN disclosed
CN-113237976-B Method for detecting impurities in diclofenac sodium 珠海润都制药股份有限公司 2023-04-07 CN disclosed
CN-115704805-A Method for detecting content of diclofenac sodium in diclofenac sodium preparation and related substances 珠海润都制药股份有限公司 2023-02-17 CN disclosed
EP-2170826-B1 PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES TECHFIELDS INC (US) 2022-04-27 EP disclosed
US-20210353579-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF TECHFIELDS PHARMA CO LTD (CN) 2021-11-18 US disclosed
CN-113402408-A Method for synthesizing diclofenac sodium 河南康达制药有限公司 2021-09-17 CN disclosed
CN-113237976-A Method for detecting impurities in diclofenac sodium 珠海润都制药股份有限公司 2021-08-10 CN disclosed
CN-111100057-B Method for synthesizing diclofenac sodium intermediate 1- (2, 6-dichlorophenyl) indoline-2-ketone 天方药业有限公司 2021-06-11 CN disclosed
CN-111116391-A Preparation method of sodium 2- [ (2, 6-dichlorophenyl) amino ] phenylacetate 浙江工业大学 2020-05-08 CN disclosed
WO-2008012602-A1 POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF DICLOFENAC WITH VERY FAST SKIN PENETRATION RATE TECHFIELDS BIOCHEM CO. LTD (CN) 2008-01-31 WO disclosed
CN-1276750-C Diclofenac sodium oral pharmaceutical NIPPON ZOKI PHARMACEUTICAL CO (JP) 2006-09-27 CN disclosed
US-20050214360-A1 Diclofenac sodium oral pharmaceutical NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2005-09-29 US disclosed
CN-1642539-A Diclofenac sodium oral pharmaceutical NIPPON ZOKI PHARMACEUTICAL CO (JP) 2005-07-20 CN disclosed
EP-1154999-A1 NITROXYDERIVATIVES HAVING ANTIINFLAMMATORY, ANALGESIC AND ANTITHROMBOTIC ACTIVITY NICOX S.A. (FR) 2001-11-21 EP disclosed
WO-2000051988-A1 NITROXYDERIVATIVES HAVING ANTIINFLAMMATORY, ANALGESIC AND ANTITHROMBOTIC ACTIVITY NICOX S.A. (FR) 2000-09-08 WO disclosed
EP-0735865-B1 EXPULSION OF MATERIAL FROM A DELIVERY DEVICE SCHERER CORP R P (US) 2000-07-12 EP disclosed
US-5897874-A DEVICE COMPRISING WATER IMPERMEABLE HOLLOW BODY CONTAINING SUBSTANCE TO BE DELIVERED AND EXPANDABLE MATERIAL, WATER SWELLABLE PLUG ENGAGED WITH NECK PORTION WHICH SWELLS AND DISENGAGES IN AQUEOUS MEDIUM R. P. SCHERER CORPORATION (US) 1999-04-27 US disclosed
EP-0735865-A1 EXPULSION OF MATERIAL FROM A DELIVERY DEVICE R.P. SCHERER CORPORATION (US) 1996-10-09 EP disclosed
WO-1995017172-A1 EXPULSION OF MATERIAL FROM A DELIVERY DEVICE R.P. SCHERER CORPORATION (US) 1995-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353579-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES KMT2A 3616/4885MEN1 4272/4885MAPT 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.